1 BTC
=
- USD
SciSparc Ltd. Ordinary Shares
As of May 30, 2026 at 24:05 UTC
Chart
About SciSparc Ltd. Ordinary Shares
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Market Statistics
Trading Metrics
How to Buy SPRC
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SPRC
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesSciSparc Ltd. (NASDAQ: SPRC) stock surged 157% on Thursday following a pre-market announcement that its majority-owned subsidiary NeuroThera Labs Inc. received conditional regulatory approval from the TSX Venture Exchange. The approval clears the path for NeuroThera to acquire a 54% majority stake in CliniQuantum Ltd., an Israeli technology company that develops quantum simulation platforms for clinical trial data analysis. The deal, valued at approximately $9.459 million, aims to improve precision in clinical trial outcomes by identifying patient subpopulations responsive to investigational therapies.
SciSparc's majority-owned subsidiary NeuroThera Labs has signed a definitive agreement to acquire approximately 54% of CliniQuantum, a quantum technology company specializing in quantum-based clinical trials. NeuroThera will issue 56.6 million common shares valued at approximately $9.46 million, with potential earn-out payments up to $2.5 million based on patent filings and fundraising milestones. The transaction is expected to close by March 31, 2026.
SciSparc's subsidiary NeuroThera Labs has signed a non-binding term sheet to acquire a 55% stake in an Israeli quantum computing bio data analysis company, aiming to leverage quantum computing principles for more efficient clinical data processing and research.
SciSparc Ltd. has entered into an agreement to acquire a controlling interest in Miza III Ventures Inc., transferring its advanced clinical stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. The transaction values the target assets at approximately $11.6 million and is expected to close around October 22, 2025.
